First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump

Journal of Medicinal Chemistry

Volumn 57, Issue 6, 2014, Pages 2536-2548

  Fontaine, Fanny ^a,b   Hequet, Arnaud ^c   Voisin Chiret, Anne Sophie ^a,b   Bouillon, Alexandre ^d   Lesnard, Aurélien ^a,b   Cresteil, Thierry ^e   Jolivalt, Claude ^c   Rault, Sylvain ^a,b  

^a NORMANDIE UNIVERSITÉ   (France)

^b CENTRE D ETUDES ET DE RECHERCHE SUR LE MÉDICAMENT DE NORMANDIE   (France)

^c PSL RESEARCH UNIVERSITY   (France)

^d BoroChem SAS   (France)

^e CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BACTERIAL PROTEIN; BORONIC ACID DERIVATIVE; CIPROFLOXACIN; DOCETAXEL; ERYTHROMYCIN; PROTEIN NORA; RESERPINE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL; BACTERIAL STRAIN; BIOLOGICAL ACTIVITY; CYTOTOXICITY; DRUG POTENTIATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BACTERIAL PROTEINS; BORONIC ACIDS; CELL SURVIVAL; CIPROFLOXACIN; CULTURE MEDIA; DRUG RESISTANCE, BACTERIAL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDICATORS AND REAGENTS; KB CELLS; MICROBIAL SENSITIVITY TESTS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84897387969     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401808n     Document Type: Article

References (70)

1. Levy, S. B.; Marshall, B. Antibacterial resistance worldwide: Causes, challenges and responses Nat. Med. 2004, 10, S122-S129
2. Prabhavathi, F. Antibacterial discovery and development-the failure of success? Nat. Biotechnol. 2006, 24, 1497-1503
3. Alekshun, M. N.; Levy, S. B. Molecular mechanisms of antibacterial multidrug resistance Cell 2007, 128, 1037-1050
4. Nikaido, H. Multidrug resistance in bacteria Annu. Rev. Biochem. 2009, 78, 119-146
5. Nordmann, P.; Naas, T.; Fortineau, N.; Poirel, L. Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010 Curr. Opin. Microbiol. 2007, 10, 436-440
6. Shon, A. S.; Russo, T. A. Hypervirulent Klebsiella pneumonia: The next superbug? Future Microbiol. 2012, 7, 669-671
7. Carlet, J.; Jarlier, V.; Harbarth, S.; Voss, A.; Goossens, H.; Pittet, D. Ready for a world without antibiotics? The pensières antibiotic resistance call to action Antimicrob. Resist. Infect. Control 2012, 1, 11-24
8. Wright, G. D. Bacterial resistance to antibiotics: Enzymatic degradation and modification Adv. Drug Delivery Rev. 2005, 57, 1451-1470
9. Lambert, P. A. Bacterial resistance to antibiotics: Modified target sites Adv. Drug Delivery Rev. 2005, 57, 1471-1485
10. Kumar, A.; Schweizer, H. P. Bacterial resistance to antibiotics: Active efflux and reduced uptake Adv. Drug Delivery Rev. 2005, 57, 1486-1513
11. McMurry, L.; Petrucci, R. E., Jr.; Levy, S. B. Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 3974-3977
12. Li, X. Z.; Nikaido, H. Efflux-mediated drug resistance in bacteria: An update Drugs 2009, 69, 1555-1623
13. Cattoir, V. Efflux-mediated antibiotics resistance in bacteria Pathol. Biol. 2004, 52, 607-616
14. Markham, P. N.; Neyfakh, A. A. Efflux-mediated drug resistance in Gram-positive bacteria Curr. Opin. Microbiol. 2001, 4, 509-514
15. Blair, J. M.; Piddock, L. J. Structure, function and inhibition of RND efflux pumps in Gram-negative bacteria: An update Curr. Opin. Microbiol. 2009, 12, 512-519
16. Piddock, L. J. V. Multidrug-resistance efflux pumps-not just for resistance Nat. Rev. Microbiol. 2006, 4, 629-636
17. Li, X. Z.; Livermore, D. M.; Nikaido, H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: Resistance to tetracycline, chloramphenicol, and norfloxacin Antimicrob. Agents Chemother. 1994, 38, 1732-1741
18. Mazzariol, A.; Cornaglia, G.; Nikaido, H. Contributions of the AmpC beta-lactamase and the AcrAB multidrug efflux system in intrinsic resistance of Escherichia coli K-12 to beta-lactams Antimicrob. Agents Chemother. 2000, 44, 1387-1390
19. Sato, T.; Yokota, S. I.; Okubo, T.; Ishihara, K.; Ueno, H.; Muramatsu, Y.; Fujii, N.; Tamura, Y. Contribution of the AcrAB-TolC eflux pump to high-level Fluoroquinolone resistance in Escherichia coli isolated from dogs and humans J. Vet. Med. Sci. 2013, 75, 407-414
20. Le Thomas, I.; Couetdic, G.; Clermont, O.; Brahimi, I.; Plésiat, P.; Bingen, E. In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy J. Antimicrob. Chemother. 2001, 48, 553-555
21. Webber, M. A.; Piddock, L. J. V. The importance of efflux pumps in bacterial antibiotic resistance J. Antimicrob. Chemother. 2003, 51, 9-11
22. Jabes, D. The antibiotic R & D pipeline: An update Curr. Opin. Microbiol. 2011, 14, 564-569
23. Hamad, B. The antibiotics market Nat. Rev. Drug Discovery 2010, 9, 675-676
24. Sader, H. S.; Flamm, R. K.; Jones, R. N. Antimicrobial activity of ceftaroline tested against Staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011 Antimicrob. Agents Chemother. 2013, 57, 3178-3181
25. Fernebro, J. Fighting bacterial infections-future treatment options Drug Resist. Updates 2011, 14, 125-139
26. Lomovskaya, O.; Bostian, K. A. Practical applications and feasibility of efflux pump inhibitors in the clinic-a vision for applied use Biochem. Pharmacol. 2006, 71, 910-918
27. Shlaes, D. M. New β-lactam-β-lactamase inhibitor combinations in clinical development Ann. N.Y. Acad. Sci. 2013, 1277, 105-114
28. Lynch, A. S. Efflux systems in bacterial pathogens: An opportunity for therapeutic intervention? An industry view Biochem. Pharmacol. 2006, 71, 949-956
29. Ippolito, G.; Leone, S.; Lauria, F. N.; Nicastri, E.; Wenzel, R. P. Methicillin-resistant Staphylococcus aureus: The superbug Int. J. Infect. Dis. 2010, 14S4, S7-S11
30. Doléans-Jordheim, A.; Michalet, S.; Bergeron, E.; Boisset, S.; Souard, F.; Dumontet, C.; Dijoux-Franca, M. G.; Freney, J. Efflux pumps: Their role in Staphylococcus aureus antibiotic resistance Ann. Biol. Clin. 2008, 66, 499-508
31. Kosmidis, C.; Schindler, B. D.; Jacinto, P. L.; Patel, D.; Bains, K.; Seo, S. M.; Kaatz, G. W. Expression of multidrug resistance efflux pump genes in clinical and environmental isolates of Staphylococcus aureus Int. J. Antimicrob. Agents 2012, 40, 204-209
32. Yoshida, H.; Bogaki, M.; Nakamura, S.; Ubukata, K.; Konno, M. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones J. Bacteriol. 1990, 172, 6942-6949
33. Neyfakh, A. A.; Borsch, C. M.; Kaatz, G. W. Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter Antimicrob. Agents Chemother. 1993, 37, 128-129
34. Handzlik, J.; Matys, A.; Kieć-Kononowicz, K. Recent advances in multi-drug resistance (MDR) efflux pump inhibitors of Gram-positive bacteria S. aureus Antibiotics 2013, 2, 28-45
35. Schmitz, F. J.; Fluit, A. C.; Lückefahr, M.; Engler, B.; Hofmann, B.; Verhoef, J.; Heinz, H. P.; Hadding, U.; Jones, M. E. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus J. Antimicrob. Chemother. 1998, 42, 807-810
36. Guz, N. R.; Stermitz, F. R.; Johnson, J. B.; Beeson, T. D.; Willen, S.; Hsiang, J. F.; Lewis, K. Flavonolignan and flavones inhibitors of Staphylococcus aureus multidrug resistance pump: Structure-activity relationships J. Med. Chem. 2001, 44, 261-268
37. Chan, B. C.; Ip, M.; Lau, C. B.; Lui, S. L.; Jolivalt, C.; Ganem-Elbaz, C.; Litaudon, M.; Reiner, N. E.; Gong, H.; See, R. H.; Fung, K. P.; Leung, P. C. Synergistic effects of baicalein with ciprofloxacin against NorA over-expressed methicillin-resistant Staphylococcus aureus (MRSA) and inhibition of MRSA pyruvate kinase J. Ethnopharmacol. 2011, 137, 767-773
38. Michalet, S.; Cartier, G.; David, B.; Mariotte, A. M.; Dijoux-Franca, M. G.; Kaatz, G. W.; Stavri, M.; Gibbons, S. N -Caffeoylphenalkylamide derivatives as bacterial efflux pump inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 1755-1758
39. Kumar, A.; Khan, I. A.; Koul, S.; Koul, J. L.; Taneja, S. C.; Ali, I.; Ali, F.; Sharma, S.; Mirza, Z. M.; Kumar, M.; Sangwan, P. L.; Gupta, P.; Thota, N.; Qazi, G. N. Novel structural analogues of piperine as inhibitors of the NorA efflux pump of Staphylococcus aureus J. Antimicrob. Chemother. 2008, 61, 1270-1276
40. Pereda-Miranda, R.; Kaatz, G. W.; Gibbons, S. Polyacylated oligosaccharides from medicinal Mexican Morning Glory species as antibacterials and inhibitors of multidrug resistance in Staphylococcus aureus J. Nat. Prod. 2006, 69, 406-409
41. Samosorn, S.; Bremner, J. B.; Ball, A.; Lewis, K. Synthesis of functionalized 2-aryl-5-nitro-1 H -indoles and their activity as bacterial NorA efflux pump inhibitors Bioorg. Med. Chem. 2006, 14, 857-865
42. Kaatz, G. W.; Moudgal, V. V.; Seo, S. M.; Kristiansen, J. E. Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus Antimicrob. Agents Chemother. 2003, 47, 719-726
43. Sabatini, S.; Kaatz, G. W.; Rossolini, G. M.; Brandini, D.; Fravolini, A. From phenothiazine to 3-phenyl-1,4-benzothiazine derivatives as inhibitors of the Staphylococcus aureus NorA multidrug efflux pump J. Med. Chem. 2008, 51, 4321-4330
44. Sabatini, S.; Gosetto, F.; Manfroni, G.; Tabarrini, O.; Kaatz, G. W.; Patel, D.; Cecchetti, V. Evolution from a natural flavones nucleus to obtain 2-(4-propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump J. Med. Chem. 2011, 54, 5722-5736
45. Pieroni, M.; Dimovska, M.; Brincat, J. P.; Sabatini, S.; Carosati, E.; Massari, S.; Kaatz, G. W.; Fravolini, A. From 6-aminoquinolone antibacterials to 6-amino-7-thiopyranopyridinylquinolone ethyl esters as inhibitors of Staphylococcus aureus multidrug efflux pumps J. Med. Chem. 2010, 53, 4466-4480
46. Sabatini, S.; Gosetto, F.; Serritella, S.; Manfroni, G.; Tabarrini, O.; Iraci, N.; Brincat, J. P.; Carosati, E.; Villarini, M.; Kaatz, G. W.; Cecchetti, V. Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: A promising new class of Staphylococcus aureus NorA efflux pump inhibitors J. Med. Chem. 2012, 55, 3568-3572
47. Bouillon, A.; Lancelot, J. C.; Collot, V.; Bovy, P. R.; Rault, S. Synthesis of halopyridinylboronic acids an esters. Part 1: 6-Halopyridin-3-yl boronic acids and esters Tetrahedron 2002, 58, 2885-2890
48. Bouillon, A.; Lancelot, J. C.; Collot, V.; Bovy, P. R.; Rault, S. Synthesis of halopyridinylboronic acids an esters. Part 2: 2, 4 or 5-Halopyridin-3-yl boronic acids and esters Tetrahedron 2002, 58, 3323-3328
49. Bouillon, A.; Lancelot, J. C.; Collot, V.; Bovy, P. R.; Rault, S. Synthesis of halopyridinylboronic acids and esters. Part 3: 2, or 3-Halopyridin-4-yl boronic acids and esters Tetrahedron 2002, 58, 4369-4373
50. Bouillon, A.; Lancelot, J. C.; Sopkova de Oliveira Santos, J.; Collot, V.; Bovy, P. R.; Rault, S. Synthesis of halopyridinylboronic acids and esters. Part 4: Halopyridin-2-yl boronic acids and esters are stable, crystalline partners for classical Suzuki cross-coupling Tetrahedron 2003, 59, 10043-10049
51. Primas, N.; Bouillon, A.; Rault, S. Recent progress in the synthesis of five-membered heterocycle boronic acids and esters Tetrahedron 2010, 66, 8121-8136
52. Dembitsky, V. M.; Al Quntar, A. A.; Srebnik, M. Natural and synthetic small boron-containing molecules as potential inhibitors of bacterial and fungal quorum sensing Chem. Rev. 2011, 111, 209-237
53. Berkers, C. R.; Leestemaker, Y.; Schuurman, K. G.; Ruggeri, B.; Jones-Bolin, S.; Williams, M.; Ovaa, H. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib Mol. Pharmaceutics 2012, 9, 1126-1135
54. Smoum, R.; Rubinstein, A.; Dembitsky, V. M.; Srebnik, M. Boron containing compounds as protease inhibitors Chem. Rev. 2012, 112, 4156-4220
55. Grassberger, M. A.; Turnowsky, F.; Hildebrandt, J. Preparation and antibacterial activities of new 1,2,3-diazaborine derivatives and analogues J. Med. Chem. 1984, 27, 947-953
56. Hernandez, V.; Crépin, T.; Palencia, A.; Cusack, S.; Akama, T.; Baker, S. J.; Bu, W.; Feng, L.; Freund, Y. R.; Liu, L.; Meewan, M.; Mohan, M.; Mao, W.; Rock, F. L.; Sexton, H.; Sheoran, A.; Zhang, Y.; Zhang, Y. K.; Zhou, Y.; Nieman, J. A.; Anugula, M. R.; Keramane, E. M.; Savariraj, K.; Reddy, D. S.; Sharma, R.; Subedi, R.; Singh, R.; O'Leary, A.; Simon, N. L.; De Marsh, P. L.; Mushtaq, S.; Warner, M.; Livermore, D. M.; Alley, M. R. K.; Plattner, J. J. Discovery of a novel class of boron-based antibacterials with activity against Gram-negative bacteria Antimicrob. Agents Chemother. 2013, 57, 1394-1403
57. Xia, Y.; Cao, K.; Zhou, Y.; Alley, M. R. K.; Rock, F.; Mohan, M.; Meewan, M.; Baker, S. J.; Lux, S.; Ding, C. Z.; Jia, G.; Kully, M.; Plattner, J. J. Synthesis and SAR of novel benzoxaboroles as a new class of β-lactamase inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 2533-2536
58. Jabbour, A.; Steinberg, D.; Dembitsky, V. M.; Moussaieff, A.; Zaks, B.; Srebnik, M. Synthesis and evaluation of oxazaborolidines for antibacterial activity against Streptococcus mutans J. Med. Chem. 2004, 47, 2409-2410
59. Benkovic, S. J.; Baker, S. J.; Alley, M. R. K.; Woo, Y. H.; Zhang, Y. K.; Akama, T.; Mao, W.; Baboval, J.; Ravi Rajagopalan, P. T.; Wall, M.; Kahng, L. S.; Tavassoli, A.; Shapiro, L. Identification of borinic esters as inhibitors of bacterial cell growth and bacterial methyltransferases CcrM and MenH J. Med. Chem. 2005, 48, 7468-7476
60. Irving, A. M.; Vogels, C. M.; Nikolcheva, L. G.; Edwards, J. P.; He, X. F.; Hamilton, M. G.; Baerlocher, M. O.; Baerlocher, F. J.; Decken, A.; Westcott, S. A. Synthesis and antifungal and antibacterial bioactivity of cyclic diamines containing boronate esters New J. Chem. 2003, 27, 1419-1424
61. Morandi, F.; Caselli, E.; Morandi, S.; Focia, P. J.; Blazquez, J.; Shoichet, B. K.; Prati, F. Nanomolar inhibitors of AmpC β-lactamase J. Am. Chem. Soc. 2003, 125, 685-695
62. Livermore, D. M.; Mushtaq, S. Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae J. Antimicrob. Chemother. 2013, 68, 1825-1831
63. Paulsen, I. T.; Brown, M. H.; Skurray, R. A. Proton-dependent multidrug efflux systems Microbiol. Rev. 1996, 60, 575-608
64. Lage, H. ABC-transporters: Implications on drug resistance from microorganisms to human cancers Int. J. Antimicrob. Agents 2003, 22, 188-199
65. Curley, K.; Pratt, R. F. Effectiveness of tetrahedral adducts as transition-state analogs and inhibitors of the class C β-lactamase of Enterobacter cloacae P99 J. Am. Chem. Soc. 1997, 119, 1529-1538
66. Negrete-Raymond, A. C.; Weder, B.; Wackett, L. P. Catabolism of arylboronic acids by Arthrobacter nicotinovorans strain PBA Appl. Environ. Microbiol. 2003, 69, 4263-4267
67. Voisin, A. S.; Bouillon, A.; Lancelot, J. C.; Rault, S. Efficient synthesis of halohydroxypyridines by hydroxydeboronation Tetrahedron 2005, 61, 1417-1421
68. Matondo, H.; Ouhaja, N.; Souirti, S.; Baboulene, M. Oxidation and Suzuki cross-coupling reaction from azaheteroarylboronic acids Main Group Met. Chem. 2002, 25, 163-167
69. Kaatz, G. W.; Seo, S. M.; Ruble, C. A. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus Antimicrob. Agents Chemother. 1993, 37, 1086-1094
70. Ross, J. I.; Eady, E. A.; Cove, J. H.; Cunliffe, W. J.; Baumberg, S.; Wootton, J. C. Inducible erythromycin resistance in staphlyococci is encoded by a member of the ATP-binding transport super-gene family Mol. Microbiol. 1990, 4, 1207-1214